- Details
To analyze visual acuity (VA) outcomes before and after preplanned treatment regimen change in the VIEW studies at week 52 (W52).
Read more: Scheduled versus Pro Re Nata Dosing in the VIEW Trials
- Details
To summarize the relative effects of bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) and ranibizumab (Lucentis; Genentech, Inc.), using findings from a Cochrane Eyes and Vision Group systematic review.
- Details
Intraocular pressure (IOP) is a major risk factor, as well as the only modifiable risk factor, for glaucoma. Racial differences have been observed in IOP measurements with individuals of African descent experiencing the highest IOP when compared with other ethnic groups. The purpose of this study was to examine the relationship between genetic ancestry and IOP in Latinos.
Read more: African Ancestry Is Associated with Higher Intraocular Pressure in Latinos
- Details
Radial retinal folds (RFs) extend from the optic disc to the peripheral retina and generally develop in utero or during the neonatal period owing to severe contractive traction caused by fibrovascular tissues in the periphery.1,2 Although RFs resemble the stalk of persistent fetal vasculature, these disorders are considered to differ. Several diseases have been reported to cause RFs, including familial exudative vitreoretinopathy (FEVR), retinopathy of prematurity, Bloch–Sulzberger syndrome, Norrie disease, and congenital toxoplasmosis.
- Details
The purpose of this study was to classify combined persistent fetal vasculature (PFV) on the basis of the ultrasonographic and Doppler characteristics. The potential clinical significance for both surgery design and prognosis determination was discussed.
- Details
Hydroxychloroquine (HCQ; Plaquenil, Sanofi-Synthelabo, Inc, Paris, France) is used to treat autoimmune diseases such as systemic lupus erythematous and rheumatoid arthritis. With long-term exposure, HCQ is known to cause a toxic retinopathy with rates varying between 1% to as high as 7.5% in patients.1 Funduscopic findings of HCQ retinal toxicity range from early, fine retinal pigment epithelium stippling of the macula to the characteristic bilateral bull's eye maculopathy.1 Cystoid macular edema (CME) has been rarely and briefly described in the literature as associated with HCQ retinal toxicity with differing interpretations regarding the angiographic features of the CME.
Read more: Nonleaking Cystoid Macular Edema as a Presentation of Hydroxychloroquine Retinal Toxicity